Abstract
The usage of targeted biologic agents in the form of monoclonal antibodies (mAbs) is rapidly expanding in the treatment of neoplastic, autoimmune, and inflammatory conditions. Consensus definitions and classification of mAbs hypersensitivity reactions are lacking. A practical approach that classifies these reactions based on their clinical presentation, underlying mechanism, and temporal presentation is suggested. These reactions include localised injection site reactions, systemic hypersensitivity reactions as well as off-target inflammatory or “paradoxical” reactions. Various biologic agents and their associated reactions are summarised. Recognition and understanding of these reactions will allow for the early diagnosis and timely management of such reactions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines—recommendations on the use of biologicals in severe asthma. Allergy. 2020;75:1023–42. https://doi.org/10.1111/all.14221.
Agache I, Rocha C, Pereira A, Song Y, Alonso-Coello P, Solà I, et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI biologicals guidelines. Allergy. 2021;76:59–70. https://doi.org/10.1111/all.14547.
Aguiar CL, Pan N, Adams A, Barinstein L, Lehman TJ. Anaphylaxis to anakinra in a pediatric patient with systemic juvenile idiopathic arthritis successfully treated with canakinumab: a case-based review. Clin Rheumatol. 2015;34:1821–4. https://doi.org/10.1007/s10067-015-2889-y.
Albers FC, Papi A, Taillé C, Bratton DJ, Bradford ES, Yancey SW, et al. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA. Respir Res. 2019;20:169. https://doi.org/10.1186/s12931-019-1134-7.
Altemir A, Iglesias-Sancho M, de los Sola-Casas MÁ, Novoa-Lamazares L, Fernández-Figueras M, Salleras-Redonnet M. Interstitial granulomatous dermatitis following tocilizumab, a paradoxical reaction? Dermatol Ther. 2020;33:10–3. https://doi.org/10.1111/dth.14207.
Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy. 2020;75:116–26. https://doi.org/10.1111/all.14080.
Baeten D, Kruithof E, van den Bosch F, van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis. 2003;62:829–34. https://doi.org/10.1136/ard.62.9.829.
Balbino B, Herviou P, Godon O, Stackowicz J, le Goff OR, Iannascoli B, et al. The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors. J Clin Investig. 2020;130:1330–5. https://doi.org/10.1172/JCI129697.
Bavbek S. Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization. Allergy. 2011;66:1256–7. https://doi.org/10.1111/j.1398-9995.2011.02599.x.
Bayer G, Agier MS, Lioger B, Lepelley M, Zenut M, Lanoue MC, et al. Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: a French nationwide study. Eur J Intern Med. 2019;67:59–64. https://doi.org/10.1016/j.ejim.2019.06.009.
Bergmann KC, Maurer M, Church MK, Zuberbier T. Anaphylaxis to mepolizumab and omalizumab in a single patient: is polysorbate the culprit? J Investig Allergol Clin Immunol. 2020;30:285–7. https://doi.org/10.18176/jiaci.0492.
Brennan PJ, Bouza TR, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124:1259–66. https://doi.org/10.1016/j.jaci.2009.09.009.
Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skin test concentrations for systemically administered drugs—an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68:702–12. https://doi.org/10.1111/all.12142.
Brown SGA. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114:371–6. https://doi.org/10.1016/j.jaci.2004.04.029.
Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, et al. Tumor necrosis factor-α inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol. 2017;76:334–41. https://doi.org/10.1016/j.jaad.2016.08.012.
Bucalo A, Rega F, Zangrilli A, Silvestri V, Valentini V, Scafetta G, et al. Paradoxical psoriasis induced by anti-TNFα treatment: evaluation of disease-specific clinical and genetic markers. Int J Mol Sci. 2020;21:1–13. https://doi.org/10.3390/ijms21217873.
Buka RJ, Knibb RC, Crossman RJ, Melchior CL, Huissoon AP, Hackett S, et al. Anaphylaxis and clinical utility of real-world measurement of acute serum tryptase in UK Emergency Departments. J Allergy Clin Immunol Pract. 2017;5:1280–1287.e2. https://doi.org/10.1016/j.jaip.2017.06.021.
Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid art. Ann Rheum Dis. 2014;73:69–74. https://doi.org/10.1136/annrheumdis-2013-203523.
Castells MC, Tennant NM, Sloane DE, Ida Hsu F, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122:574–80. https://doi.org/10.1016/j.jaci.2008.02.044.
Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355–66. https://doi.org/10.1016/S2213-2600(15)00042-9.
Choo KJL, Simons FER, Sheikh A. Glucocorticoids for the treatment of anaphylaxis. Evidence-Based Child Health. 2013;8:1276–94. https://doi.org/10.1002/ebch.1925.
Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13:725–32. https://doi.org/10.1634/theoncologist.2008-0012.
Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233–40. https://doi.org/10.1016/j.semarthrit.2010.04.003.
Cox L, Platts-Mills TAE, Finegold I, Schwartz LB, Simons FER, Wallace DV. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120:1373–7. https://doi.org/10.1016/j.jaci.2007.09.032.
Daïen CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology. 2009;48:883–6. https://doi.org/10.1093/rheumatology/kep046.
Dogra S, Bishnoi A, Narang T, Handa S. Secukinumab-induced paradoxical pustular psoriasis. Clin Exp Dermatol. 2019;44:72–3. https://doi.org/10.1111/ced.13731.
Emmi G, Silvestri E, Cantarini L, Lopalco G, Cecchi L, Chiarini F, et al. Rapid desensitization to anakinra-related delayed reaction: need for a standardized protocol. J Dermatol. 2017;44:981–2. https://doi.org/10.1111/1346-8138.13619.
Eyerich S, Onken AT, Weidinger S, Franke A, Nasorri F, Pennino D, et al. Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med. 2011;365:231–8. https://doi.org/10.1056/nejmoa1104200.
Faivre C, Villani AP, Aubin F, Lipsker D, Bottaro M, Cohen JD, et al. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol. 2016;74:1153–9. https://doi.org/10.1016/j.jaad.2016.01.018.
Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatol Treat. 2019;59(2):253–6. https://doi.org/10.1080/09546634.2019.1682503.
FDA. Highlights of prescribing information (Secukinumab). White Oak, MD: FDA; 2015.
FDA. Highlights of prescribing information. REMICADE (infliximab) for 2020. White Oak, MD: FDA; 2018.
FDA. Full prescribing information (Tocilizumab). White Oak, MD: FDA; 2019a.
FDA. FDA Ixekizumab. Ixekizumab FDA. Highlights of prescribing information. White Oak, MD: FDA; 2019b.
Finkelman FD, Khodoun MV, Strait R. Human IgE-independent systemic anaphylaxis. J Allergy Clin Immunol. 2016;137:1674–80. https://doi.org/10.1016/j.jaci.2016.02.015.
FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–41. https://doi.org/10.1016/S0140-6736(16)31322-8.
Fouda GE, Bavbek S. Rituximab hypersensitivity: from clinical presentation to management. Front Pharmacol. 2020;11:572863. https://doi.org/10.3389/fphar.2020.572863.
Fowler E, Silverberg JI, Fox JD, Yosipovitch G. Psoriasiform dermatitis after initiation of treatment with dupilumab for atopic dermatitis. Dermatitis. 2019;30:234–6. https://doi.org/10.1097/DER.0000000000000481.
Galvão VR, Castells MC. Hypersensitivity to biological agents-updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract. 2015;3:175–85. https://doi.org/10.1016/j.jaip.2014.12.006.
Ghosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, et al. Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn’s disease: an integrated analysis of phase II/III clinical development programs. Drug Saf. 2019;42:751–68. https://doi.org/10.1007/s40264-019-00797-3.
Gülsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches. Allergo J Int. 2020;29:139–54. https://doi.org/10.1007/s40629-020-00127-5.
Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84:139–47. https://doi.org/10.1016/j.jaad.2020.08.051.
Hayakawa M, Izumi K, Higashida-Konishi M, Ushikubo M, Tsukamoto M, Akiya K, et al. Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review. Rheumatol Int. 2019;39:161–6. https://doi.org/10.1007/s00296-018-4175-1.
Hong D, Sloane DE. Hypersensitivity to monoclonal antibodies used for cancer and inflammatory or connective tissue diseases. Ann Allergy Asthma Immunol. 2019;123:35–41. https://doi.org/10.1016/j.anai.2019.04.015.
Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, De Vita S, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre registry. Clin Exp Rheumatol. 2015;33:449–56.
Isabwe GAC, Sanchez LDLV, Castells M. Management of adverse reactions to biologic agents. Allergy Asthma Proc. 2017;38:409–18. https://doi.org/10.2500/aap.2017.38.4085.
Isabwe GAC, Garcia Neuer M, de las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018;142:159–170.e2. https://doi.org/10.1016/j.jaci.2018.02.018.
Iznardo H, Puig L. The safety of brodalumab for the treatment of psoriasis. Expert Opin Drug Saf. 2020;19:365–72. https://doi.org/10.1080/14740338.2020.1730326.
Izquierdo JH, Bonilla-Abadía F, Ochoa CD, Agualimpia A, Tobón GJ, Cañas CA. Acute generalized exanthematous pustulosis due to tocilizumab in a rheumatoid arthritis patient. Case Rep Rheumatol. 2012;2012:1–2. https://doi.org/10.1155/2012/517424.
Jackson K, Bahna SL. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases. Expert Rev Clin Immunol. 2020;16:311–9. https://doi.org/10.1080/1744666X.2020.1724089.
Jani M, Dixon WG, Kersley-Fleet L, Bruce IN, Chinoy H, Barton A, et al. Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open. 2017;3. https://doi.org/10.1136/rmdopen-2016-000314.
Jaros J, Hendricks AJ, Shi VY, Lio PA. A practical approach to recalcitrant face and neck dermatitis in atopic dermatitis. Dermatitis. 2020;31:169–77. https://doi.org/10.1097/DER.0000000000000590.
Jönsson F, De Chaisemartin L, Granger V, Gouel-Chéron A, Gillis CM, Zhu Q, et al. An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis. Sci Transl Med. 2019;11:eaat1479. https://doi.org/10.1126/scitranslmed.aat1479.
Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol. 2012;30:700–6.
Kaiser C, Knight A, Nordström D, Pettersson T, Fransson J, Florin-Robertsson E, et al. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int. 2012;32:295–9. https://doi.org/10.1007/s00296-011-2096-3.
Lecluse LLA, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008;159:527–36. https://doi.org/10.1111/j.1365-2133.2008.08728.x.
Li SJ, et al. TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis. 2019;4:70–80. https://doi.org/10.1177/2475530318810851.TNF.
Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9:806–15. https://doi.org/10.1093/ecco-jcc/jjv096.
Lieberman PL, Umetsu DT, Carrigan GJ, Rahmaoui A. Anaphylactic reactions associated with omalizumab administration: analysis of a case-control study. J Allergy Clin Immunol. 2016;138:913–915.e2. https://doi.org/10.1016/j.jaci.2016.03.030.
Ma HL, Napierata L, Stedman N, Benoit S, Collins M, Nickerson-Nutter C, et al. Tumor necrosis factor α blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of treg cells. Arthritis Rheum. 2010;62:430–40. https://doi.org/10.1002/art.27203.
Makowska J, Lewandowska-Polak A. Desensitization to biological agents used in rheumatology. Reumatologia. 2020;58:26–33. https://doi.org/10.5114/reum.2020.93510.
Martorell-Calatayud A. Interstitial granulomatous drug reaction to adalimumab. Am J Dermatopathol. 2010;32:408–9. https://doi.org/10.1001/archdermatol.2011.241.
Massolino RI, Hissaria P, Lee A, Proudman SM. Tocilizumab-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient with rheumatoid arthritis. Rheumatol Adv Pract. 2018;2:1–2. https://doi.org/10.1093/rap/rky029.
Mazloom SE, Yan D, Hu JZ, Ya J, Husni ME, Warren CB, et al. TNF-α inhibitor–induced psoriasis: a decade of experience at the Cleveland Clinic. J Am Acad Dermatol. 2020;83:1590–8. https://doi.org/10.1016/j.jaad.2018.12.018.
Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev. 2009. https://doi.org/10.1002/14651858.CD005121.pub3.
Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc JL. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. Rheumatology. 2014;53:1864–71. https://doi.org/10.1093/rheumatology/keu214.
Mufti A, Sachdeva M, Kim P, Rahat S, Lytvyn Y, Maliyar K, et al. A systematic review of eczematous eruptions in patients receiving biologic therapy. J Am Acad Dermatol. 2021;85(6):1630–5. https://doi.org/10.1016/j.jaad.2020.11.071.
Murdaca G, Spanò F, Puppo F. Selective TNF-α inhibitor-induced injection site reactions. Expert Opin Drug Saf. 2013;12:187–93. https://doi.org/10.1517/14740338.2013.755957.
Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. J Am Acad Dermatol. 2022;86(5):1080–91. https://doi.org/10.1016/j.jaad.2020.12.010.
Nakamura M, Lee K, Singh R, Zhu TH, Farahnik B, Abrouk M, et al. Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: a review. J Dermatol Treat. 2017;28:237–41. https://doi.org/10.1080/09546634.2016.1230173.
Navarro R, Daudén E. Clinical management of paradoxical psoriasiform reactions during TNF-α therapy. Actas Dermo-Sifiliograficas. 2014;105:752–61. https://doi.org/10.1016/j.adengl.2013.05.011.
O’Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1–6. https://doi.org/10.1097/01.MIB.0000436951.80898.6d.
Ou Z, Chen C, Chen A, Yang Y, Zhou W. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol. 2018;54:303–10. https://doi.org/10.1016/j.intimp.2017.11.031.
Owens G, Petrov A. Successful desensitization of three patients with hypersensitivity reactions to omalizumab. Curr Drug Saf. 2012;6:339–42. https://doi.org/10.2174/157488611798918692.
Perino E, Freymond N, Devouassoux G, Nicolas JF, Berard F. Xolair-induced recurrent anaphylaxis through sensitization to the excipient polysorbate. Ann Allergy Asthma Immunol. 2018;120:664–6. https://doi.org/10.1016/j.anai.2018.02.018.
Picard M, Galvão VR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. J Allergy Clin Immunol Pract. 2017;5:600–9. https://doi.org/10.1016/j.jaip.2016.12.001.
Puxeddu I, Giori L, Rocchi V, Bazzichi L, Bombardieri S, Tavoni A, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol. 2012;108:123–4. https://doi.org/10.1016/j.anai.2011.11.004.
Régnier Galvão V, Castells MC, Paulo S. Hypersensitivity to biological agents—updated diagnosis. J Allergy Clin Immunol Pract. 2015. https://doi.org/10.1016/j.jaip.2014.12.006.
Resuscitation Council copyright U. Anaphylaxis algorithm; 2008.
Reyn B, Hillary T, Gils A. Eczematous eruption after guselkumab treatment for psoriasis. JAAD Case Rep. 2019;5:973–5. https://doi.org/10.1016/j.jdcr.2019.09.005.
Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44:355–62. https://doi.org/10.1111/1346-8138.13622.
Saint Marcoux B, de Bandt M. Vasculitides induced by TNFα antagonists: a study in 39 patients in France. Joint Bone Spine. 2006;73:710–3. https://doi.org/10.1016/j.jbspin.2006.02.010.
Saito Y, Hayashi S, Gonmori T, Hamasaki Y, Igawa K. Interrupting tocilizumab therapy-induced psoriasis-like eruption in a patient with rheumatoid arthritis and Crohn’s disease. Int J Dermatol. 2020;59:e159–60. https://doi.org/10.1111/ijd.14809.
Sala-Cunill A, Luengo O, Cardona V. Biologics and anaphylaxis. Curr Opin Allergy Clin Immunol. 2019;19:439–46. https://doi.org/10.1097/ACI.0000000000000550.
Sanan N, Schend J, Rowane M, Hostoffer R. Expedited desensitization to canakinumab. Allergy Rhinol. 2020;11:215265672093769. https://doi.org/10.1177/2152656720937694.
Santos RB, Galvão VR. Monoclonal antibodies hypersensitivity: prevalence and management. Immunol Allergy Clin N Am. 2017;37:695–711. https://doi.org/10.1016/j.iac.2017.07.003.
Sehgal VN, Pandhi D, Khurana A. Biologics in dermatology: adverse effects. Int J Dermatol. 2015;54:1442–60. https://doi.org/10.1111/ijd.12802.
Shaker MS, Wallace DV, Golden DBK, Oppenheimer J, Bernstein JA, Campbell RL, et al. Anaphylaxis—a 2020 practice parameter update, systematic review, and grading of recommendations, assessment, development and evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020;145:1082–123. https://doi.org/10.1016/j.jaci.2020.01.017.
Shankar T, Petrov AA. Omalizumab and hypersensitivity reactions. Curr Opin Allergy Clin Immunol. 2013;13:19–24. https://doi.org/10.1097/ACI.0b013e32835bf3f5.
Sheikh A, ten Broek VM, Brown SG, Simons FER. H1-antihistamines for the treatment of anaphylaxis with and without shock. Cochrane Database Syst Rev. 2007;2007. https://doi.org/10.1002/14651858.cd006160.pub2.
Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2012;87:739–45. https://doi.org/10.1016/j.mayocp.2012.04.011.
Sparsa L, Afif N, Bularca S, Fricker A, Thiebault S, Dahan E, et al. Réactions cutanées paradoxales sous traitement par tocilizumab. Rev Med Interne. 2014;35:613–6. https://doi.org/10.1016/j.revmed.2014.01.007.
Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–28. https://doi.org/10.1056/nejmoa063842.
Thomaidou E, Ramot Y. Injection site reactions with the use of biological agents. Dermatol Ther. 2019;32:1–4. https://doi.org/10.1111/dth.12817.
Thomas L, Canoui-Poitrine F, Gottenberg JE, Economu-Dubosc A, Medkour F, Chevalier X, et al. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry. J Rheumatol. 2012;39:893–8. https://doi.org/10.3899/jrheum.111347.
Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567–77. https://doi.org/10.1136/gutjnl-2012-302853.
Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016;2:1–12. https://doi.org/10.1136/rmdopen-2015-000239.
Truong A, et al. Nummular dermatitis on guselkumab for palmoplantar psoriasis. Dermatol Ther. 2019;32:e12954. https://doi.org/10.1111/dth.12954.Nummular.
Urosevic-Maiwald M, Harr T, French LE, Dummer R. Stevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer. Int J Dermatol. 2012;51:864–7. https://doi.org/10.1111/j.1365-4632.2011.05356.x.
Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1921–7. https://doi.org/10.1016/S0140-6736(16)00560-2.
Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67:567–70. https://doi.org/10.1136/ard.2007.075663.
WHO. Revised monoclonal antibody (mAb) nomenclature scheme programme on International Nonproprietary Names (INN) Technologies Standards and Norms Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP). Geneva: World Health Organization; 2017.
de Wijs LEM, Nguyen NT, Kunkeler ACM, Nijsten T, Damman J, Hijnen DJ. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2020;183:745–9. https://doi.org/10.1111/bjd.18730.
Ya J, Hu JZ, Nowacki AS, Khanna U, Mazloom S, Kabbur G, et al. Family history of psoriasis, psychological stressors, and tobacco use are associated with the development of tumor necrosis factor-α inhibitor-induced psoriasis: a case-control study. J Am Acad Dermatol. 2020;83:1599–605. https://doi.org/10.1016/j.jaad.2020.06.081.
Yang SY, Lan CC, Hu SCS. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by golimumab. Int J Dermatol. 2017;56:571–2. https://doi.org/10.1111/ijd.13565.
Yilmaz I, Türk M, Bahçecioğlu SN. Successful rapid subcutaneous desensitization to anakinra in a case with a severe immediate-type hypersensitivity reaction. Eur Ann Allergy Clin Immunol. 2018;50:94–6. https://doi.org/10.23822/EurAnnACI.1764-1489.30.
Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor α receptor: Fc fusion protein. Arch Dermatol. 2001;137:893–9.
Zhu GA, Chen JK, Chiou A, Ko J, Honari G. Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155:850–2. https://doi.org/10.1001/jamadermatol.2019.0109.
Zuelgaray E, Domont F, Peiffer-Smadja N, Saadoun D, Cacoub P. Tocilizumab-induced drug reaction with eosinophilia and systemic symptoms syndrome in adult-onset still disease. Ann Intern Med. 2017;167:141–2. https://doi.org/10.7326/L16-0592.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Choo, K.J.L., Yeo, Y.W. (2022). Cutaneous Adverse Reactions to Biologic Agents. In: Lee, H.Y., Creamer, D. (eds) Drug Eruptions. Updates in Clinical Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-031-09388-3_24
Download citation
DOI: https://doi.org/10.1007/978-3-031-09388-3_24
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-09387-6
Online ISBN: 978-3-031-09388-3
eBook Packages: MedicineMedicine (R0)